June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Suppression of Laser-induced Choroidal Neovascularization Using Promiscuous Cytokine Antagonist
Author Affiliations & Notes
  • Shira Levi
    Department of Ophthalmology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
  • Michal Abraham
    Goldyne Savad Institute of Gene Therapy, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
  • Liran Tiosano
    Department of Ophthalmology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
  • Batya Rinsky
    Department of Ophthalmology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
  • Michelle Grunin
    Department of Ophthalmology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
  • Amnon Peled
    Goldyne Savad Institute of Gene Therapy, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
    Biokine Therapeutics Ltd., Science Park, Ness Ziona, Israel
  • Itay Chowers
    Department of Ophthalmology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
  • Footnotes
    Commercial Relationships Shira Levi, None; Michal Abraham, None; Liran Tiosano, None; Batya Rinsky, None; Michelle Grunin, None; Amnon Peled, Biokine Therapeutics Ltd., Science Park, Ness Ziona, Israel (E), Biokine Therapeutics Ltd., Science Park, Ness Ziona, Israel (I), Biokine Therapeutics Ltd., Science Park, Ness Ziona, Israel (P); Itay Chowers, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 6181. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Shira Levi, Michal Abraham, Liran Tiosano, Batya Rinsky, Michelle Grunin, Amnon Peled, Itay Chowers; Suppression of Laser-induced Choroidal Neovascularization Using Promiscuous Cytokine Antagonist. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):6181.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Monocytes/macrophages were suggested to exert a proangiogenic effect in the context of neovascular age-related macular degeneration (nvAMD). Several cytokines in addition to vascular endothelial growth factor may potentially mediate such an effect. We aim to explore simultaneous perturbation of several cytokines as a potential therapeutic strategy for choroidal neovascularization (CNV).

Methods: Laser injury induced CNV was generated in Long-Evans rats (n=15). BKT130, a promiscuous antagonist of several cytokines including MCP1, MIP-3A, IP-10, Mig, I-TAC, TARK and RANTES, was delivered via intraperitoneal (IP) injection (4 mg) at the day of laser injury and five days later. Control rats received IP PBS. CNV was evaluated via fluorescein angiogram (FA) that was performed 10 days following the laser injury. Retina flatmounts immunostained for CD11b served to quantify subretinal macrophages, and retinal pigment epithelium-choroid flatmounts stained with isolectin were utilized to quantify CNV.

Results: Masked quantification of isolectin staining showed a mean suppression of CNV area of 26% (p=0.0058; Mann Whitney test). CD11b immunostaining showed a mean of 23% reduction of subretinal macrophages number following BKT130 therapy (p=0.0011; Mann Whitney test). Systemic or ocular side effects were not identified.

Conclusions: These data further supports the putative pathogenic role of macrophages and their cytokine products in CNV growth. It also suggests that targeting multiple cytokines simultaneously using a single compound (polypharmacology) may potentially serve as a therapeutic strategy for the disease.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×